Recent News

• 09.17.2025 - Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
• 09.10.2025 - Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
• 09.03.2025 - Cantor Global Healthcare Conference
• 08.26.2025 - Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
• 08.13.2025 - Canaccord Genuity 45th Annual Growth Conference
• 08.13.2025 - Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
• 08.05.2025 - Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
• 06.16.2025 - Sagimet Biosciences Virtual KOL Event - A New Mechanism of Action in Treating Acne

Recent Filings

• 08.22.2025 - 8-K Current report
• 08.14.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - 8-K Current report
• 08.13.2025 - EX-99.1 EX-99.1
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.13.2025 - 8-K Current report
• 07.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.23.2025 - 4 Statement of changes in beneficial ownership of securities